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The possibility of altered B-adrenergic receptors and/or adenyl cyclase 
activity in fibroblasts from patients with cystic fibrosis (CF) has been 
raised by several groups of investigators. Buchwald (1) reported a greater 
increase in CAMP’ after isoproterenol stimulation in CF than in normal 
fibroblasts and this was confirmed by Roscher et al. (2) for CF and 
normal fibroblasts in fresh medium. Furthermore, CF fibroblasts were 
shown to be more resistant to the cytotoxic effects of exogenous dibutyrl 
CAMP or isoproterenol than were normal fibroblasts (3). However, Buch- 
wald and Mapelson (4) and Davis et al. (5) could not reproduce these 
differences in response to isoproterenol between CF and normal cultured 
skin fibroblasts. The CAMP response of fibroblasts to isoproterenol is 
known to be highly sensitive to time and cell density in culture (6) and 
the negative reports on differences between CF and normal fibroblasts 
(4,5) noted high day-to-day variability. We have studied the response to 
metaproterenol (a congener of isoproterenol) of pairs of CF and normal 
fibroblast strains compared blind on the same day and found greater 
responses in the CF strains. We have sought the basis for this difference 
by measuring B-adrenergic receptors and find increased binding capacity 
for a P-adrenergic antagonist. 
METHODS 
Fibroblasts were obtained either from the Human Genetics Mutant 
Cell Repository or from patients at the University of Michigan Hospital. 
The cell lines were grown as monolayers at 37°C in 5% CO, in polystyrene 
tissue culture flasks (obtained from Corning). Eagle’s basal medium with 
‘Abbreviations used: CAMP, adenosine cyclic 3’,5’-monophosphate; CF, cystic fibrosis: 
[‘HIDHA, [‘Hldihydroalprenolol; N. normal control. 
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Earle’s salts was supplemented with 10% bobby calf serum, glutamine 
(30 mg/lOO ml), and 1% penicillin-streptomycin (all from Gibco). The 
cells were fed every 4 days and split approximately once a week. 
The cultured skin fibroblasts or amniocentesis-derived cells were 
treated with 10s5 M metaproterenol for 30 min. The medium was decanted 
leaving 0.5 ml and cells were rapidly (< 30 set) scraped with a rubber 
policeman. Aliquots were immediately pipetted into centrifuge tubes 
positioned in a boiling water bath and heated at 97°C for 10 min. The 
tubes were cooled to 0°C and centrifuged at 800g for 15 min and aliquots 
of the supernatant fluid were assayed for CAMP by the Gilman protein- 
binding method (7) while the pellet was analyzed for protein by the 
method of Lowry et al. (8). The cross-reactivity of the CAMP antiserum 
with cyclic GMP was < 0.00008%, as indicated in the technical infor- 
mation with the CAMP [‘251]RIA kit (obtained from New England 
Nuclear). 
To assay p-adrenergic receptors, the cells were prepared for assay by 
washing twice with 0.05 M Tris-buffered saline, pH 7.4, and scraping 
with a rubber policeman. (Trypsin cannot be used because of the sen- 
sitivity of the P-adrenergic receptor to proteolytic degradation.) The cell 
suspension was then centrifuged at 15Og and the pellet resuspended to 
approximately 30 mg protein/ml. B-Adrenergic receptors were measured 
by a competitive binding assay with the potent P-adrenergic antagonist, 
[3H]dihydroalprenolol ([3H]DHA), essentially as described by Mukherjee 
and Lefkowitz (9). The reaction was carried out in a total volume of 500 
~1, containing 400 ~1 cell suspension, 10 nM [3H]DHA, and either 10 PM 
(+-) propranolol or an equivalent amount of buffer. The assay was in- 
cubated for 10 min at 37°C and terminated by adding ice-cold Tris buffer 
and emptying the sample over a Whatman GF/C filter. The filters were 
washed thoroughly with buffer, dried, and counted in Instagel scintillation 
fluid. Protein content was determined by the method of Lowry et al. 
(8). The specific binding, expressed as femtomoles per microgram pro- 
tein, was calculated as the difference between total binding U3H]DHA 
only) and nonspecific binding ([3H]DHA and excess propranolol). 
Plasma membranes were prepared from both the CF and normal fi- 
broblasts, essentially as described by Kartner et al. (10). The cells were 
washed four times with 20 ml PBS and swollen with 25 ml of 1 mM 
NaHCO,, pH 7.4, for 1 min at room temperature. This hypotonic pro- 
cedure was repeated and the cells were removed from the surface by 
manual shaking. The cell suspension was made 0.5 mM in EDTA, pH 
7.4, and centrifuged for 20 min at 27,000g. The resulting pellet was 
resuspended in 5 ml of 10% (w/v) sucrose, layered on a discontinuous 
density gradient made up of 5 ml each of 30, 48, and 60% sucrose, and 
centrifuged at 76,000g for 2 hr in a SW27.1 rotor. Material banding at 
the interfaces was collected by aspiration, washed free of sucrose with 
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1 mM NaHCO,, pH 7.4, and centrifuged at 33,000g for 20 min. The 
fraction from the lo-30 interface was reported to contain plasma mem- 
branes (10) and this fraction was used in subsequent binding studies with 
both CF and normal lines. 
RESULTS 
We could consistently distinguish CF fibroblasts from normal lines 
when presented “blind” and as pairs. Under these conditions, CF fi- 
broblasts showed 1.5 to 2.5fold greater induction of CAMP compared 
to normal fibroblasts after incubating the cells with 10e5 M metaproter- 
enol, an analog of isoproterenol (Table 1). There was some overlap in 
the actual values from experiment to experiment, but within any one 
experiment there was always an increased induction of CAMP in the CF 
fibroblasts. 
The time dependency of [3H]dihydroalprenolol (L3H]DHA) binding was 
performed in the presence and absence of a large excess of unlabeled 
propranolol and specific binding (total nonspecific) was found to be op- 
timal after 10 min at 37°C. This time was used in all further experiments. 
Saturation experiments were performed using varying concentrations of 
[3H]DHA (2-40 nM) with both cell types. The saturation curve obtained 
using normal cells, shown in Fig. 1, appears to plateau at approximately 
10 nM [3H]DHA. That obtained with the CF cells, however, shown in 
Fig. 2, did not reach saturation at the hormone concentrations used. This 
TABLE 1 
INDUCTION OF CAMP IN FIBROBLASTS FROM CF PATIENTS AND NORMAL CONTROLS WITH 
METAPROTERENOL 
Treatment Cell line 
Metaproterenol N1 











Note. t = 2.4; P < 0.05. 
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FIG. 2. Saturation curve for cystic fibrosis fibroblasts at varying concentrations of 
[‘H]dihydroalprenolol. 
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suggests a difference in affinity between the CF and normal fibroblast 
P-adrenergic receptor but, due to assay variation, a Scatchard plot was 
not meaningful. Saturation studies using [3H]dihydroalprenolol on several 
tissues indicate the apparent equilibrium dissociation constant, K,,, to 
be 12-15 nM (11). We decided to continue to compare normal and CF 
fibroblast binding of [3H]DHA at 10 nM, this concentration being below 
the K,, since the normal receptor was saturated at this concentration 
and it has been the usual concentration used on a variety of cell types. 
The mean “specific binding” for each CF and normal line as well as 
the cumulative means when assayed at the standardly used concentration 
of 10 nM, are shown in Table 2. The threefold increase in CF cells is 
statistically significant by Student’s t test (P < 0.001). Although we have 
found some overlap between CF and normal lines from one experiment 
to another, on a given day, the CF lines consistently showed increased 
P-adrenergic binding compared to normal cells. This is clearly shown by 
the CF/N ratio for each experiment, given in Table 3, and is significant 
by the Wilcoxon rank sum test at P = 0.0011. 
To confirm that we are dealing with cell surface receptors, P-adrenergic 
binding was measured on purified plasma membranes of CF and normal 
TABLE 2 
SPECIFIC BINDING TO P-ADRENERGIC RECEPTORS IN CYSTIC FIBROSIS AND NORMAL 
FIBROBLASTS 
Line x SE n 
GM280 1 0.46 
GM1959 0.65 
GM770 0.88 






























Total 0.25 0.03 29 
Nore. r (45) = 0.0949; P = 0.001 
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TABLE 3 
SPECIFIC BINDING RATKJ-CYSTIC FIBROSIS TO 
NORMAL 








8 I .58 
9 2.61 
Note. P (w, 2 120) = 0.0011. 
fibroblasts (Table 4). The membrane extracts from CF fibroblasts showed 
7.15 ? 0.16 fmole/kg protein specifically bound while those from normal 
cells showed 2.7 -+ 0.65 fmole/pg protein. The lo-fold enrichment in p- 
adrenergic receptor in plasma membranes in both cases argues that the 
difference between CF and normal fibroblasts is not due to differences 
in compartmentalization of receptor. 
DISCUSSION 
There is increased stimulation of several types of autonomic nervous 
system glands such as the salivary gland in patients with CF (12,13). 
Evidence suggests that the altered exocrine secretions in these patients 
could be due to altered autonomic nervous system receptors in exocrine 
cells (14). Cultured skin fibroblasts from patients with CF seem to exhibit 
this altered membrane property. We have found a greater induction of 
CAMP in CF fibroblasts than in normal fibroblast cells when they are 
TABLE 4 
SPECIFIC BINDING ON PURWIED PLASMA MEMBRANES 






Total .% 7.15 2.17 
SE 0.16 0.65 
Now. r (3) = 7.90; P = 0.01. 
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incubated with B-adrenergic agonists. The CF fibroblasts, therefore, ex- 
hibit “supersensitivity” to B-adrenergic agonists with respect to normal 
fibroblast cells. The increased response could, a priori, be due to several 
factors, such as increased amount of B-adrenergic receptors, increased 
adenylate cyclase activity, or decreased PDE activity. The accompanying 
paper (15) shows that the high K,,, form of CAMP phosphodiesterase is 
increased, not decreased. Thus, we measured specific binding of the B- 
adrenergic antagonist, [3H]dihydroalprenolol. Although the saturation 
kinetics of binding were different in CF and normal fibroblasts, con- 
sistently more [3H]DHA was bound by CF than by normal fibroblasts 
when assayed at the standard concentration of 10 nM. This difference 
in binding was also found in the approximately lo-fold-enriched plasma 
membrane fraction. Buckwald and Riordan (16) did not find an increase 
in B-adrenergic receptors when studied on fibroblasts attached to plastic. 
Although our, and some other, studies suggest increased B-adrenergic 
sensitivity, in viva studies and studies on lymphocytes have suggested 
decreased production of CAMP in cystic fibrosis: when corrected to 
cyclic GMP excretion, cystic fibrosis patients secreted less CAMP in 
urine than did normal controls (17), were less sensitive to isoproterenol- 
stimulated increases in blood pressure (IQ, and CF lymphocytes showed 
a decreased response of CAMP to isoproterenol stimulation (19). In this 
regard, it may be that fibroblasts are more similar to the pupil of the eye 
which shows increased responses to both adrenergic and cholinergic 
agonists in viva (18). The decreased responses of cardiac muscle and 
lymphocytes to isoproterenol might also reflect down regulation of B- 
adrenergic receptors. 
SUMMARY 
We have found that CAMP is induced to a greater extent in cultured 
cystic fibrosis fibroblast cell lines than in normal lines using a p-adren- 
ergic agonist. By using the potent B-antagonist, [3H]dihydroalprenolol 
in a competitive radioligand binding assay, we measured B-adrenergic 
specific binding on skin fibroblasts derived from cystic fibrosis patients 
and normal individuals. The CF cells were found to have 0.73 ? 0.12 
fmole/pg protein specifically bound, while normal cells showed 0.25 t 
0.03 fmole/pg protein. Even though this difference is highly statistically 
significant, we found some overlap between the two cell types from one 
experiment to another. In any given experiment, however, the CF cells 
consistently showed increased B-adrenergic binding when compared to 
normal controls. Binding was measured on plasma membrane extracts 
from CF and normal fibroblasts. The CF lines continued to show in- 
creased specific binding compared to normal lines when partially purified 
plasma membranes were assayed. The B-adrenergic binding capacity of 
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partially purified plasma membranes was significantly higher (10 times) 
than the values obtained with whole cells in both cases. 
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